Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxycycline plus autologous blood patch versus autologous blood patch alone for persistent air leak in secondary spontaneous pneumothorax
PACTR202505753650802Phase 0Recruiting
- Sponsor
- King Saud Medical City
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 0, randomised, open-label trial of doxycycline in secondary spontaneous pneumothorax (SSP) (2 arms), sponsored by King Saud Medical City. Primary endpoint: Complete cessation of air leak. Started Jan 2025; status: recruiting.
02
Drugs
doxycycline
03
Conditions
secondary spontaneous pneumothorax (SSP)
Beyond the preview
Go deeper on PACTR202505753650802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202505753650802.